摘要
心肌纤维化是多种心血管疾病发展到一定阶段的共同病理改变。心肌细胞的细胞再生能力有限,其损伤后的主要修复机制即心肌纤维化。心肌纤维化过程中形成瘢痕组织,在维持心脏结构完整性的同时会导致心脏舒张、收缩功能受损,并在损伤修复中持续加重。半乳糖凝集素-3作为心肌纤维化重要调节分子,是延缓或阻断心肌纤维化的新靶标。现总结最近半乳糖凝集素-3在心肌纤维化相关心血管疾病中的研究进展,以期探寻心肌纤维化过程中的治疗靶点。
Myocardial fibrosis is a common pathological change in the development of a variety of cardiovascular diseases to a certain stage. Cardiomyocytes have limited ability to regenerate cells, and the main repair mechanism after injury is myocardial fibrosis. The formation of scar tissue during myocardial fibrosis can lead to diastolic and systolic function injury while maintaining the structural integrity of the heart, and it continues to worsen in the repair of the injury. Galectin-3, as an important regulator of myocardial fibrosis, is a new target for delaying or blocking myocardial fibrosis. This review summarizes the recent advances in study of galectin-3 in cardiovascular disease associated with myocardial fibrosis in order to explore therapeutic targets during myocardial fibrosis.
作者
屈建新
邢冬梅
刘新灿
QU Jianxin;XING Dongmei;LIU Xincan(Henan University of Traditional Chinese Medicine, Zhengzhou 450000, Henan,China)
出处
《心血管病学进展》
CAS
2019年第4期605-608,共4页
Advances in Cardiovascular Diseases
基金
国家自然科学基金(81703889)
河南省中医药专项研究课题(2017ZY2038)
